The FDA record for P220024 identifies Advanced Medical Solutions Limited as the applicant for two hernia mesh fixation devices, LIQUIFIX FIX8 for laparoscopic repair and LIQUIFIX Precision for open repair of groin hernias. The original approval was decided on June 2, 2023, and a later supplement, P220024/S007, was decided on October 23, 2026, covering a revised post-approval study protocol. The supplied filings show two linked PMA records, both approvals, and no recall sample. [1][2][6]
The applicant and the approved devices
The approval letter for P220024 is addressed to Advanced Medical Solutions Limited at Western Wood Way, Langage Science Park, Plymouth, Devon, and names Rose Guang as Vice President, Regulatory & Clinical Affairs. The same letter lists the trade names LiquiFix FIX8 and LiquiFix Precision and records the application as filed October 27, 2022, with amendments in March, April and May 2023. The decision letter is signed by Binita S. Ashar, Director of OHT4: Office of Surgical and Infection Control Devices. [6]
The approval order describes the intended use of each device. LIQUIFIX FIX8 is intended for laparoscopic surgical repair of groin hernias, both inguinal and femoral, through fixation of prosthetic polypropylene or polyester mesh to the abdominal wall and approximation of the peritoneum. LIQUIFIX Precision is intended for open surgical repair of groin hernias through fixation of prosthetic polypropylene or polyester mesh to the abdominal wall. [2]
Filing details and product classification
The PMA record lists the generic name as tissue adhesive internal use, device class 3, regulation number 878.4010, product code PLJ, and advisory committee General, Plastic Surgery. The original application carries docket number 23M-2807 and a Federal Register notice date of July 28, 2023, and it was not flagged for expedited review. [2]
The supplement P220024/S007 was received September 25, 2026 and decided October 23, 2026 under decision code APPR. Its supplement type is Normal 180 Day Track No User Fee and its supplement reason is Postapproval Study Protocol. The same classification fields, including product code PLJ and the General, Plastic Surgery advisory committee, appear on the supplement record. [1]
Post-approval study scope
The approval order for S007 states that the supplement approves a revised protocol addressing patient enrollment issues in the LIQUIFIX Post-Approval Study. The changes combine the laparoscopic and open devices into a single body of evidence and revise patient sample sizes for both devices. The statement notes that the protocol was submitted to comply with conditions of approval in the original approval order for P220024. [1]
The FDA post-approval studies database describes the agency's authority to require sponsors to perform post-approval studies at the time of approval of a premarket approval application. The database pages retrieved for this study identifier contain navigation and general program text rather than study results. [7][10]
Company-published product description
A LIQUIFIX product page published under the LiquiBand brand describes LIQUIFIX as atraumatic mesh fixation for open and minimally invasive inguinal and femoral hernia repair. The page states that the devices affix mesh and peritoneal tissue with liquid anchors and are designed to eliminate the need for penetrating mechanical tacks, sutures or staples, and it identifies LIQUIFIX as a registered trademark of Advanced Medical Solutions Limited. These are the publisher's characterizations, not FDA findings. [8]



